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Acute myeloid leukemia (AML) is a malignant disorder characterized by increased 
proliferation and blocked differentiation of a hematopoietic stem cell clone. AML has a 
highly heterogeneous genetic background with more than two hundred different cytogenetic 
and molecular genetic aberrations. Acquired cytogenetic abnormalities are the most important 
leukemia-related prognostic factors for treatment outcome and survival and are divided into 3 
prognostic groups: favorable, intermediate and adverse. The favorable cytogenetic risk group 
covers the structural changes of genes affecting the subunits of the core-binding factor (CBF): 
t(8;21), inv 16, t(16;16) in detail, or the RARA gene: t(15;17). The adverse cytogenetic risk 
group includes: deletions of 5, 5q, 7, 7q, 17p, inv(3)(q21;q26), t(3;3)(q21;q26), 
rearrangements of (11q23) except t(9;11) and complex karyotypes (defined as either ≥three or 
≥five abnormalities). The intermediate cytogenetic risk group consists of other abnormalities, 
which do not belong either to the favorable or to adverse cytogenetic groups. Testing for 
molecular acquired genetic mutations helps for the risk stratification in different cytogenetic 
subgroups, especially in patients with normal karyotype (NK). 
A common mutation occurring in about 25% of AML and 35% of NK-AML patients is the 
internal tandem duplications (ITD) of the fms-like tyrosine kinase 3 (FLT3) gene, which 
encodes for a receptor tyrosine kinase. FLT3-ITDs occur in the juxtamembrane domain 
(JMD) or in the tyrosine kinase domain 1 (TKD1), resulting in constitutive activation of this 
receptor. FLT3-ITD AML accounts for a distinct subgroup of AML with well-known clinical 
features, and impaired treatment outcome due to increased relapse rate. The most frequent 
acquired, recurrent mutation identified in approximately 35% of AML and 55% of NK-AML 
patients is a 4 basepair long insertion in the nucleophosmin 1 gene (NPM1). The mutation 
alters the nuclear localization signal of the NPM1 protein resulting in a dominant cytoplasmic 
localization. AML patients harboring this mutation have a better prognosis.  
A new type of recently identified, acquired genetic alteration in AML affects mutational 
hotspots of isocitrate dehydrogenase 1 and 2 (IDH1, codon 132 and IDH2 codons 140 and 
172). Under normal circumstances, IDH enzymes catalyze the conversion of isocitrate to α–
ketoglutarate (αKG). The presence of IDH mutant enzymes results in aberrant production of 
2-hydroxyglutarate (2HG), resulting in the block of αKG dependent enzymes such as tet 
methylcytosine dioxygenases 1 and 2 (TET1 and 2), or histone demethylases causing global, 




impaired stem cell differentiations. IDH
mut 
AML also characterized by distinct clinical 
features, but data on its prognostic impact were controversial.  
The clinical manifestation and the treatment outcome of AML depend not only on the 
acquired mutations in the malignant clone, but also on the inherited genetic variations of the 
individual patient affecting eg. pharmacokinetics. The ATP-binding cassette, sub-family G, 
member 2 (ABCG2) multidrug transporter is preferentially expressed in pharmacological 
barriers, (liver, kidney, placenta, blood-brain barrier). This protein modulates the absorption, 
metabolism and toxicity of numerous drugs and xenobiotics, and causes multidrug resistance 
in cancer. Interestingly, ABCG2 was also found to be expressed in stem cells (including 
haematopoietic and leukemic stem cells in AML). ABCG2 expression on stem cells 
presumably plays a protective role against various endo- and exotoxins. ABCG2 expression 
may be responsible for the development of multidrug resistance during chemotherapy. Many 
SNPs causing mis-trafficking and early degradation were identified in the coding region of 
ABCG2 gene. To date, among the most studied variants the following two nonsynonymous 
single nucleotide polymorphisms (SNP) are represented: V12M (c.34G>A), and Q141K 
(c.421C>A). V12M has not yet been associated with any deviation in protein expression or 
function. On the other hand, Q141K, with a variable allele frequency between 5-30% in 
various ethnic groups but preferentially occurring in Asian populations, was found to decrease 
protein expression in vitro, and to reduce drug efflux and ATPase activity. 
Detailed characterization of acquired and inherited genetic background in malignant 





Aims of the study 
Impact of acquired mutations (FLT3, NPM1, IDH1/2) in AML 
Recent studies suggest that personalized medicine is an important tool in order to choose 
the most optimal therapy for cancer patients. Detailed characterization of acquired genetic 
background in malignant disorders, such as AML, is essential in risk stratification and in 
selection of the most optimal therapy, for each patient. Our aims were the following in the 
context of acquired mutations: 
1. To set up and optimize a PCR followed by a capillary electrophoresis in order to 
calculate the frequencies of FLT3-ITDs and NPM1 mutations in our AML cohort. 
2. To study the association between FLT3-ITD load, size and clinical characteristics or 
treatment outcome in AML. 
3. To set up three different detection methods (allele specific PCR, high resolution 
melting and sequencing) in order to calculate the frequencies of IDH1/2 mutations in AML. 
4. To verify the clinical and the prognostic relevance of different IDH1/2 mutations in 
AML. 
 
ABCG2 genetic variations in healthy individuals and in AML patients 
Inherited genetic variations have also been found to play a great role in the clinical 
manifestation and the treatment outcome of AML patients. They account for risk stratification 
and choice of therapy in order to achieve the best outcome. In connection, our aims were the 
following 
1.  To develop an antibody-based quantitative flow cytometric assay for the determination 
of membrane proteins including ABCG2 on red blood cell (RBC) membranes. 
2.  To test the effect of common ABCG2 polymorphic variants (V12M and Q141K) on 
ABCG2 protein expression on RBC membrane in healthy individuals. 
3.  To investigate the effect of genetic variants on disease susceptibility, clinical 







1) Genotyping was completed on 389 AML patients (FLT3-ITD n=324, IDH n=376, ABCG2 
SNP n=389) [183 males/206 females; median age: 50; range: (16-93 years)] diagnosed 
and followed between 2001 and 2009. Treatment outcome was investigated in patients 
younger than 65 years old and treated with curative intension (n=324, n=314, n=307 in 
FLT3-ITD, IDH and ABCG2 studies respectively). 
2) The determination of ABCG2 protein expression level on red blood cells (RBC) was 
performed in 61 healthy volunteers (47 unrelated individuals and 14 family members of 
two probands selected from the volunteers). 
3) A control group, consisting of 202 healthy unrelated individuals was screened for 
ABCG2 SNPs (V12M, Q141K). 
Molecular genetic methods 
All mutation analyses (FLT3-ITD, NPM1, IDH1/2), were performed from genomic DNA 
isolated from bone marrow or peripheral blood samples at the time of diagnosis. ABCG2 
expression level was also investigated at the time of diagnosis, but from mRNA isolated from 
the bone marrow. ABCG2 SNPs testing was performed from genomic DNA isolated from 
bone marrow or peripheral blood samples at diagnosis or any time during follow-up. 
FLT3-ITD and NPM1 mutational status was defined according to the detected fluorescently 
labeled PCR product on capillary electrophoresis (fragment analysis). The FLT3-ITD load 
was quantified as the ratio of the peak height of the FLT3-mutant allele divided by the sum of 
the mutant and the wild type peak heights (ITD/ITD+WT). 
IDH1 and IDH2 mutations were screened by high resolution melting (HRM) and by allele-
specific PCR (AS-PCR). Samples, which showed IDH1positivity by AS-PCR and HRM, were 
sequenced in order to identify the exact type of mutation. For IDH2, those samples were 
sequenced, which gave contradictory results by AS-PCR and HRM. 
The most common SNPs in ABCG2 (V12M) and (Q141K) were genotyped using the 
LightCycler480 (Roche Diagnostics, Basel, Switzerland) allelic discrimination system. The 
coding region of ABCG2 gene, (exons 2-16) and the exon-intron boundaries were 




Flow cytometry (FACS) 
FACS analysis was performed from freshly drawn peripheral blood using monoclonal 
antibodies specifically recognizing ABCG2 (BXP21 and BXP34-recognizing an intracellular 
ABCG2 epitope and 5D3 recognizing an ABCG2 extracellular epitope). 
Statistical analysis 
Continuous variables are presented as median and range. The Mann-Whitney or the 
Kruskal-Wallis tests were used to compare continuous variables in subgroups according to 
FLT3-ITD mutation status, different ITD load and size and IDH mutation status. Fischer’s 
exact test and the χ2 tests were performed to compare dichotomous variables. Genotype and 
allele frequencies with 95% confidence interval (AF ± 95%CI) are presented. Estimated 
haplotype frequencies (EHF) were calculated by the web-based SNPStats web tool. The log-
rank test was used to compare disease free survival (DFS) and overall survival (OS) between 
groups separated by ITD load and size or IDH mutation status or ABCG2 genotypes. A Cox 
proportional hazards model was computed for multivariate analysis of OS and DFS with the 
calculation of hazard ratio (HR) and 95% confidence interval (95%CI). The statistics were 





Impact of acquired mutations (FLT3, NPM1, IDH1/2) in AML 
FLT3-ITD mutations were detected in 82/388 (21.1%) cases. The presence of ITD was 
related to de novo AML etiology (p<0.001). It associated more frequently with 
myelomonocyter morphology (p=0.0004). FLT3-ITD
pos
 patients presented with significantly 
higher white blood cell (WBC) counts at diagnosis (p<0.001). FLT3-ITD
pos
 associated with 
intermediate risk cytogenetics (p<0.001) and NPM1 mutation (p<0.001). In our entire patient 
cohort, FLT3-ITD
pos
 itself did not associate with adverse prognosis, only relapse rate seemed 




 subgroup showed better 
OS and DFS in the intermediate and normal karyotype subgroups. 
The median FLT3-ITD load was 26%. Using 50% as a cut-off, clinical characteristics at 
presentation (sex, etiology of AML, morphology, blood counts, cytogenetics and NPM1), 
were not different between FLT3-ITD
pos
 individuals with low ITD load (FLT3-ITD
<50%
; 
n=56) vs. high ITD load (FLT3-ITD
>50%
; n=15). Treatment outcome was investigated in 43 
FLT3-ITD
<50%
 and 15 FLT3-ITD
>50%
 patients. Regarding the outcome parameters, presence of 
higher FLT3-ITD load resulted in worse DFS and OS (p=0.010, 0.038 respectively). 
The size of FLT3-ITD varied from 6 to 210 base pair (bp). 22/81 patients (27.2%) 
displayed more than one mutant amplicons (size calling was possible in 81/82 FT3-ITD 
positive cases). FLT3-ITD mutants with insertion length shorter or longer than 48bp showed 
similar clinical characteristics at diagnosis, but profoundly different treatment outcome in the 
entire AML group. Longer ITDs were associated with higher early death ratio (p=0.01); a 
tendency toward higher relapse rate (p=0.06); resulting in worse OS (p=0.02) and DFS 
(p=0.005). Patients with FLT3-ITD
>48bp
 had worse OS and DFS compared to ITD negative 
patients (n=255; p=0.04; p=0.013 respectively). Interestingly individuals with longer than 
60bp insertions (FLT3-ITD
>60bp
; n=15) showed better OS and DFS compared to patients with 
insertion between 48 and 60bp (FLT3-ITD
48-60bp
; n=15, p=0.014; p=0.019 respectively), 
indicating that medium sized ITD confers the worst prognosis among ITD positive patients. 
IDH1 and IDH2 mutations were mutually exclusive, detected in 32 (8.5%) and 28 cases 
(7.5%). All mutations were in heterozygous form. In IDH1, R132C (n=14, 43.7%) and 
R132H (n=10, 31.2%) substitutions were the most frequent. In IDH2, R140Q (n=20, 71.4%) 
and R172K (n=8; 28.6%) were identified. IDH mutations combined were associated with: 




NPM1 mutation (p=0.022) as well as with a lower mRNA expression level of ABCG2 gene 
(p=0.006) at diagnosis. Remission rate, relapse rate, overall survival (OS) were not different 
in IDH1 mutant (n=24) vs. IDH1 and 2 wild type (n=269) or in IDH2 mutant (n=21) vs. IDH1 
and 2 wild type. Marked differences in the clinical presentation were observed between IDH1 
R132H and R132C mutant AML patients. R132H mutant AML cases were more likely to 
have de novo origin (90%), while R132C positive AMLs were secondary to myelodysplastic 
syndrome (MDS), or therapy related in 50% of cases (p=0.08). FAB M1 was more common 
in R132C (p=0.02). PLT count at diagnosis was higher in R132H (p=0.050). Interestingly, 
particular IDH mutations differed in association with NPM1 mutations: concomitant IDH and 
NPM1 mutations occurred in 14.3% (2/14) of IDH1 R132C vs. 70% (7/10) R132H carriers 
(p=0.02) and in 47.4% (9/20) of IDH2 R140Q vs. 0% (0/8) R172K carriers (p=0.02). IDH1 
R132H (n=9) negatively influenced OS compared to IDH1 and 2 wild type (p=0.02) or to 
R132C (n=9, p=0.019). No differences were found comparing various IDH2 mutations with 
respect to treatment outcome. 
ABCG2 genetic variations in healthy individuals and in AML patients 
ABCG2 expression on RBC 
ABCG2 protein expression on RBC did not associate with age or sex. Among the 47 
donors, there were 11 individuals with heterozygous Q141K variant (allele frequency: 
11.7±6.6%), and 3 individuals with heterozygous V12M variant (allele frequency: 3.2±3.6%) 
genotypes. Individuals carrying the heterozygous ABCG2 Q141K variant exhibited 
significantly lower expression of ABCG2 (5.27±1.19) on RBC, as compared to homozygous 
wild-type individuals (6.13±0.61, p=0.011). There was no significant difference between 
homozygous wild-type individuals and heterozygous V12M carriers. 
 ABCG2 nonsense mutations 
Two unrelated individuals out of 47 exhibited lower RBC ABCG2 expression 
(2.65±0.29). Sequencing of the ABCG2 gene in these cases revealed two different 
heterozygous nonsense mutations: (1) an arginine to stop codon change in exon 7 (c.706C>T, 
p.R236X, rs140207606) and (2) a small deletion also in exon 7 (c.791_792delTT, 
p.L264HfsX14). Low ABCG2 expression phenotypes were segregated in both families with 






ABCG2 V12m and Q141K in AML 
Genotype and allele frequencies (AF) were not different in AML patients as a whole cohort 
compared to controls. On the other hand, AML subgroup analysis revealed that RUNX1-
RUNX1T1 t(8;21)(q22;q22) translocation] positive patients (n=18) showed higher V12M AF 
compared to control individuals (p=0.02). Among AML patients younger than 60 years 
receiving daunorubicin based induction chemotherapy (n=256), ABCG2 141K carriers 
displayed longer overall (p=0.072) and disease free survival (p=0.048) compared to 
individuals carrying the major allele in homozygous form (QQ genotype). Early death due to 
toxicity, resistant disease, remission and relapse rates were not different between ABCG2 







Impact of acquired mutations (FLT3, NPM1, IDH1/2) in AML 
Our results suggest that the length of FLT3-ITD mutations may influence disease outcome, 
in a way that medium-sized ITDs (48-60 bp) may confer worse prognosis than shorter or 
longer mutations. As a possible explanation, ITD was reported to lead to the constitutive 
activation of the kinase domain by disrupting the autoinhibitory interaction between the 
juxtamembrane domain and activation loop. In line with this hypothesis, longer ITDs could 
lead to more profound destabilization of the inactive kinase. On the other hand, longer ITDs 
were reported to be inserted more C-terminally in the FLT3 protein, which may cause 
increased interference with the kinase activity, leading to a reduced transforming capacity. 
IDH1 and 2 mutations are associated with distinct clinical characteristics.  Alterations in 
NPM1 associations between IDH1 R132C and R132H or between IDH2 R140Q and R172K 
suggest differences between particular mutations. IDH substitutions are generally considered 
as a weak prognostic factors influencing survival in an inconsistent way in different AML 
subgroups, which may originate from different amino acid changes affecting outcome in 
opposite ways. Our observations may suggest that specific mutations might differ in the level 
of 2HG production or they might act differently on other pathways besides blocking αKG -
dependent enzymes. 
ABCG2 genetic variations in healthy individuals and in AML patient 
Based on our results, FACS may be a rapid and reliable assay for the quantitative 
determination of membrane protein expression in human erythrocytes. We found significant 
differences in ABCG2 expression levels between homozygous wild-type and heterozygous 
141K polymorphic variant carriers. Our further observations suggest that the ABCG2 genetic 
variants associated with the absence of high frequency blood group antigens (p.R236X, 
p.L264HfsX14) may be more common than previously described. Our results also suggest 
that common ABCG2 polymorphisms might influence AML predisposition and treatment 
outcome differentially depending on AML genetic background or chemotherapy applied. 
In summary, we conclude that that mutational profiling can be important and useful for 
risk stratification and therapeutical decisions. Therefore detailed characterization of acquired 
and inherited genetic background in malignant disorders, such as AML is necessary in 





AML has a highly heterogeneous acquired genetic background. Each of AML patients 
harbors an unique set of mutations and molecular features characterizing the disease. 
Mutational profiling of acquired and inherited variants can be important and useful for risk 
stratification guided therapeutical decisions. One of the most frequent mutations affects FLT3 
gene: the internal tandem duplication (ITD) in FLT3 autoinhibitory juxtamembrane region 
causing a permanent receptor signal transduction and uncontrolled proliferation of leukemic 
cells. Another recently identified, acquired aberration affects mutational hotspots of isocitrate 
dehydrogenase 1 and 2 (IDH1 codon 132 and IDH2 codons 140 and 172). The inherited 
polymorphic variants of ATP-binding cassette multidrug transporter, sub-family G, member 2 
(ABCG2 V12M and Q141K) may influence drug transport during chemotherapy. 
In this work I focused on the impact of acquired mutations (FLT3-ITD, IDH1/2) and 
inherited polymorphisms (ABCG2) on the clinical manifestation and treatment outcome in 
AML and on impact of ABCG2 inherited variations on ABCG2 protein expression in healthy 
individuals. 
FLT3-ITD was detected in 21% of AML cases. Patients with higher ITD load or medium 
size insertions (between 48 and 60bp) showed worse treatment outcome and survival 
compared to patients with lower load or insertions with other size. IDH1 and IDH2 mutations 
were mutually exclusive, detected in 8% and 7% of AML cases respectively. IDH1 R132H 
negatively influenced survival compared to IDH1/2 wild type or to R132C.  
Healthy individuals carrying the heterozygous ABCG2 Q141K variant exhibited 
significantly lower expression of ABCG2 protein in red blood cell membrane, as compared to 
homozygous wild-type individuals. Sequencing of the ABCG2 gene of two unrelated 
individuals showing lower erythrocyte ABCG2 expression revealed heterozygous mutations 
resulting in premature termination (R236X, L264HfsX14). ABCG2 Q141K positively 
influenced survival in patients with daunorubicin-based treatment regimens. 
Detailed characterization of acquired and inherited genetic variants in malignant disorders, 
such as AML helps to predict prognosis and to apply risk adapted treatment strategies aiming 
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